For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential ...